Skip to main content
. 2020 Dec 23;38(2):1185–1201. doi: 10.1007/s12325-020-01589-3

Table 4.

CKD + SCH (baseline TSH > 10 mIU/L): CKD progression at 6, 12, 18, and 24 months

n = 25 P value SMD
Treatment cohort (n = 15) Nontreatment cohort (n = 10)
n % n %
CKD progression from BL at:
 6 months 1 6.7 3 30.0 0.1190 60.3
 12 months 2 13.3 3 30.0 0.3074 39.4
 18 months 3 20.0 4 40.0 0.2752 42.7
 24 months 3 20.0 5 50.0 0.1152 63.3

BL baseline, CKD chronic kidney disease, SCH subclinical hypothyroidism, SMD standardized mean difference, TSH thyroid-stimulating hormone